#

 *June 2018 Enquiries: Chris Pockett, Head of Communications +44 (0)1453 524133*

**Renishaw exhibits at Canadian Neurological Sciences Federation Congress**

From June 24th to June 27th, 2018, global engineering technologies company Renishaw will attend the Canadian Neurological Sciences Federation’s annual congress. The event, held at the Halifax Convention Centre, Nova Scotia, provides multidisciplinary courses relevant to all neuroscience specialities. On booth 304, Renishaw will showcase its *neuromate*® stereotactic robot and *neuroinspire*™ its surgical planning software.

The *neuromate* robot has been used in thousands of electrode implantation procedures including deep brain stimulation (DBS) for Parkinson’s disease and stereoelectroencephalography (SEEG), a procedure used in epilepsy diagnosis. The robot provides consistent, rapid and precise targeting in neurosurgical procedures and removes the need for a stereotactic frame.

Renishaw’s *neuroinspire* surgical planning software provides the tools to assist with the planning of most stereotactic procedures. It integrates with the *neuromate* stereotactic robot and provides the ability to carry out peri-operative verification.

“The Canadian Neurological Sciences Federation’s annual congress is a great opportunity for Renishaw to meet both existing and potential customers,” explained Adrian Gut, Global Sales and Marketing Director of Renishaw’s Neurological Products Division. “Renishaw already contributes to the Additive Design in Surgical Solutions (ADEISS) Centre in London, Canada as a result of its partnership with Western University and the London Medical Network. However, there is considerable potential for further collaboration in Canada.”

“The robot totally changes how we approach insertion of SEEG electrodes,” commented David A. Steven, Associate Professor of Neurosurgery, Western University, London, Ontario. “It is noticeably faster and more accurate than the previous system. In addition, it allows us to plan trajectories previously impossible with a standard frame, making surgery safer and more accurate.”

For more information on Renishaw’s neurological product range, visit [http://www.renishaw.com/ neuro](file:///C%3A%5CUsers%5Clp138190%5CAppData%5CLocal%5CMicrosoft%5CWindows%5CINetCache%5CContent.Outlook%5C931ZYKWO%5Cwww.renishaw.com%5C%20neuro).

Ends 274 words

Notes to editors

UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to dentistry and brain surgery. It has over 4,500 employees located in the 35 countries where it has wholly owned subsidiary operations.

For the year ended June 2017 Renishaw recorded sales of £536.8 million of which 95% was due to exports. The company’s largest markets are China, the USA, Japan and Germany.

Throughout its history Renishaw has made a significant commitment to research and development, with historically between 14 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

Further information at [www.renishaw.com](http://www.renishaw.com)